Long-term follow-up from the National Institutes of Health reported outcomes from eight CLL patients who received anti-CD19 CAR-T cell FMC63-28Z, later known as axicabtagene ciloleucel (axi-cel) [118]. Here, CD19 is linked to B-cell chronic lymphocytic leukemia.